Key result
Gut microbiota and metabolites bidirectionally modulate statin lipid-lowering efficacy and glycemic adverse effects.
Why the study?
Individual responses to statin therapy vary considerably, and emerging evidence links the gut microbiota to drug metabolism and response, potentially modulating statin efficacy and adverse effects.
How does the gut microbiota interact with statin therapy to influence lipid-lowering efficacy and adverse metabolic effects in patients with cardiovascular diseases?
How does the gut microbiota interact with statin therapy to influence lipid-lowering efficacy and adverse metabolic effects in patients with cardiovascular diseases?
Understanding the bidirectional interaction between the gut microbiota and statins offers a promising pathway to optimize lipid-lowering efficacy and mitigate statin-induced insulin resistance through personalized microbiome-targeted interventions.
Answers are grounded in this paper and cite their sources.
May support microbiota-targeted interventions to optimize statin therapy; hypothesis-generating and should not yet change practice.
Statins, known as HMG-CoA reductase inhibitors, are widely utilized to reduce blood cholesterol levels and possess pleiotropic effects, including the influence on inflammation and macrophage proliferation. Despite their significant impact in diminishing the incidence of cardiovascular events and mortality, individual responses to statin therapy vary considerably. Understanding this variability is essential for optimizing treatment outcomes and minimizing adverse effects. The gut microbiota, a complex ecosystem of microorganisms within the gastrointestinal tract, plays a critical role in human health and disease. Emerging evidence has linked the gut microbiota to drug metabolism and response, with the potential to modulate the efficacy of statin therapy and its side effects. This review provides a comprehensive overview of the interaction between the gut microbiota and statins. It discusses how the gut microbiota can influence the therapeutic effects and side effects of statins and examines the mechanisms by which the gut microbiota affect statin response and cardiovascular diseases.
No takes yet. Share an insight, caveat, or question.
She et al. (2024) conducted a review in Cardiovascular diseases and hyperlipidemia. Statin therapy and gut microbiota modulation was evaluated. Gut microbiota composition and secondary metabolites (TMAO, SCFAs, and bile acids) bidirectionally modulate the lipid-lowering efficacy and glycemic adverse effects of statin therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: